Zydus is lined up to copy 6 of the blockbuster drugs on this tracker, which earned $72.7B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Zydus's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Entresto | Novartis | Generic | 2025 | Approved Jul 2024 | $7.7B |
| Farxiga | AstraZeneca | Generic | 2026 | Approved Apr 2026 | $8.4B |
| Lynparza | AstraZeneca / Merck | Generic | 2027 | Generic filed; in litigation | $3.3B |
| Otezla | Amgen | Generic | 2028 | Barred by court until Feb 2028 | $2.3B |
| Ozempic | Novo Nordisk | Generic | 2032 | Settled, terms confidential | ≈$19.3B |
| Keytruda FYB206 |
Merck | Biosimilar | 2028 | Phase 1 complete; US filing planned | $31.7B |
Company facts: Stock Analysis. Each drug page lists sources for these entries. Brand sales show the size of the market, not Zydus's share of it.